| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07c9542186133097bd6bbb7d92393090
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f3b719e471d3c60a6effcec64bd9e3f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4577a5200186457fceddd6ad0fa48795
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00924da5ad2b0e91dcd35bab32529f78 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2602-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-1804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C401-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C401-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2011-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7375765c24f00ba976bba607e9ca7919
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f2ffcbb5564855687eb5923f6440086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da066289969fe657e9e653f1f5d93a79 |
| publicationDate |
2012-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012065050-A1 |
| titleOfInvention |
22-haloacetoxy-homopregnacalciferol analogs and their uses |
| abstract |
This invention discloses 22-haloacetoxy-homopregnacalciferol analogs and specifically 22-bromoacetoxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits relatively little calcemic activity and does not promote cellular differentiation of HL-60 leukemia cells, but rather kills the cells. This cell death activity is found in small cell lung carcinoma also, but not in prostate cancer cells. This compound thus causes specific cell death in the absence of changes in calcium levels and without general toxicity in an animal. Therefore it might serve as a useful therapy for treatment of some forms of cancer, such as leukemia and lung cancer. |
| priorityDate |
2010-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |